Innova launches nano-gold antibody tech; Imprimis snags delivery compound for eye surgery recovery;

> Innova Biosciences launched its site-specific bioconjugation technology for attaching antibodies to gold nanoparticles with more control over the orientation of the antibodies. More

> Imprimis Pharmaceuticals ($IMMY) acquired a compound for the delivery of anti-inflammatory and antibacterial agents into the eye. Release

> Arena Pharmaceuticals ($ARNA) completed a Phase I trial of its oral prostacyclin receptor agonist APD811 for the treatment of arterial hypertension. The company plans to begin Phase II in the beginning of 2014. Release

> Mallinckrodt ($MNK) said it would present clinical data next week on its extended-release oral oxycodone and acetaminophen formulation MNK-795 at PAINWeek 2013 in Las Vegas. Release

> Orexo reported successful results from a Phase II study of its sublingual formulation of alfentanil, a pain management drug for surgical and invasive diagnostic procedures. Release

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.